[Therapeutic concentrations of theophylline and caffeine during treatment of apnea in premature infants with theophylline]. 1985

D Alix, and F Berthou, and C Riche, and H Gouedard

Theophylline has been administered to 76 premature infants with apnea in two therapeutic indications: curative and preventive treatment. Plasmatic theophylline and caffeine concentrations have been performed by gas chromatography for ten days for the determination of the therapeutic range. The maximum effective concentration has been defined from the data observed in 33 subjects presenting with symptoms considered as signs of toxicity. The minimum effective concentration has been determined from the data observed during the failure of treatment (n = 4) and at the reappearance of apnea at the end of treatment (n = 10). The therapeutic concentrations of theophylline has be found on average to be 3 to 8 mg/l and for the theophylline and caffeine together from 5 to 10 mg/l. The sum theophylline and caffeine data is better for therapeutic monitoring than the determination of theophylline alone.

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007235 Infant, Premature, Diseases Diseases that occur in PREMATURE INFANTS.
D002110 Caffeine A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine's most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes SMOOTH MUSCLE, stimulates CARDIAC MUSCLE, stimulates DIURESIS, and appears to be useful in the treatment of some types of headache. Several cellular actions of caffeine have been observed, but it is not entirely clear how each contributes to its pharmacological profile. Among the most important are inhibition of cyclic nucleotide PHOSPHODIESTERASES, antagonism of ADENOSINE RECEPTORS, and modulation of intracellular calcium handling. 1,3,7-Trimethylxanthine,Caffedrine,Coffeinum N,Coffeinum Purrum,Dexitac,Durvitan,No Doz,Percoffedrinol N,Percutaféine,Quick-Pep,Vivarin,Quick Pep,QuickPep
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001049 Apnea A transient absence of spontaneous respiration. Apneas
D013806 Theophylline A methyl xanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Theophylline inhibits the 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE that degrades CYCLIC AMP thus potentiates the actions of agents that act through ADENYLYL CYCLASES and cyclic AMP. 1,3-Dimethylxanthine,3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione,Accurbron,Aerobin,Aerolate,Afonilum Retard,Aquaphyllin,Armophylline,Bronchoparat,Bronkodyl,Constant-T,Elixophyllin,Euphylong,Glycine Theophyllinate,Lodrane,Monospan,Nuelin,Nuelin S.A.,Quibron T-SR,Slo-Phyllin,Somophyllin-T,Sustaire,Synophylate,Theo Von Ct,Theo-24,Theo-Dur,Theobid,Theocin,Theoconfin Continuous,Theodur,Theolair,Theolix,Theon,Theonite,Theopek,Theophylline Anhydrous,Theophylline Sodium Glycinate,Theospan,Theostat,Theovent,Uniphyl,Uniphyllin,Uniphylline,1,3 Dimethylxanthine,Anhydrous, Theophylline,Constant T,ConstantT,Ct, Theo Von,Glycinate, Theophylline Sodium,Quibron T SR,Quibron TSR,Slo Phyllin,SloPhyllin,Sodium Glycinate, Theophylline,Somophyllin T,SomophyllinT,Theo 24,Theo Dur,Theo24,Theophyllinate, Glycine,Von Ct, Theo
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

D Alix, and F Berthou, and C Riche, and H Gouedard
December 1981, Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde,
D Alix, and F Berthou, and C Riche, and H Gouedard
January 1990, Archives francaises de pediatrie,
D Alix, and F Berthou, and C Riche, and H Gouedard
July 1985, American journal of diseases of children (1960),
D Alix, and F Berthou, and C Riche, and H Gouedard
September 1989, Acta paediatrica Scandinavica,
D Alix, and F Berthou, and C Riche, and H Gouedard
November 1976, The Journal of pediatrics,
D Alix, and F Berthou, and C Riche, and H Gouedard
June 1979, The Journal of pediatrics,
D Alix, and F Berthou, and C Riche, and H Gouedard
December 1990, Archives francaises de pediatrie,
D Alix, and F Berthou, and C Riche, and H Gouedard
March 1980, The Journal of pediatrics,
D Alix, and F Berthou, and C Riche, and H Gouedard
December 1982, Medical hypotheses,
D Alix, and F Berthou, and C Riche, and H Gouedard
April 1979, Lancet (London, England),
Copied contents to your clipboard!